View Item 

Show simple item record

Prognostic factors in laryngeal squamous cell carcinoma
dc.contributor.authorBradford, Carol R.
dc.contributor.authorFerlito, Alfio
dc.contributor.authorDevaney, Kenneth O.
dc.contributor.authorMäkitie, Antti A.
dc.contributor.authorRinaldo, Alessandra
dc.date.accessioned2020-03-17T18:35:34Z
dc.date.availableWITHHELD_12_MONTHS
dc.date.available2020-03-17T18:35:34Z
dc.date.issued2020-02
dc.identifier.citationBradford, Carol R.; Ferlito, Alfio; Devaney, Kenneth O.; Mäkitie, Antti A. ; Rinaldo, Alessandra (2020). "Prognostic factors in laryngeal squamous cell carcinoma." Laryngoscope Investigative Otolaryngology 5(1): 74-81.
dc.identifier.issn2378-8038
dc.identifier.issn2378-8038
dc.identifier.urihttps://hdl.handle.net/2027.42/154535
dc.description.abstractBackgroundThe current treatment results of laryngeal squamous cell carcinoma still remain modest. Various prognostic factors have been investigated and need to be included in the management decision making.MethodsWe reviewed the pertinent literature regarding host, tumor, and treatment factors as prognostic indicators that influence outcome in patients diagnosed with laryngeal squamous cell carcinoma.ResultsHost, tumor, and treatment factors all have an important impact upon an individual patient’s prognosis with laryngeal squamous cell carcinoma, whereas staging systems only take into account tumor factors. There is much work yet to be done to establish reliable, independent biomarkers that predict survival and response to treatment.ConclusionsOptimal outcomes for an individual patient can be achieved when taking into account tumor, host, and treatment factors.
dc.publisherJohn Wiley & Sons, Inc.
dc.subject.otherlaryngeal squamous cell carcinoma
dc.subject.otherprognostic factors
dc.subject.otheroverall survival
dc.titlePrognostic factors in laryngeal squamous cell carcinoma
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOtolaryngology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/154535/1/lio2353.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/154535/2/lio2353_am.pdf
dc.identifier.doi10.1002/lio2.353
dc.identifier.sourceLaryngoscope Investigative Otolaryngology
dc.identifier.citedreferenceMilroy CM, Ferlito A, Devaney KO, Rinaldo A. Role of DNA measurements of head and neck tumors. Ann Otol Rhinol Laryngol. 1997; 106: 801 ‐ 804.
dc.identifier.citedreferenceWolf GT, Carey TE. Tumor antigen phenotype, biologic staging, and prognosis in head and neck squamous carcinoma. J Natl Cancer Inst Monogr. 1992; 13: 67 ‐ 74.
dc.identifier.citedreferenceWolf GT, Fisher SG, Truelson JM, Beals TF. DNA content and regional metastases in patients with advanced laryngeal squamous carcinoma. Department of Veterans Affairs Laryngeal Study Group. Laryngoscope. 1994; 104: 479 ‐ 483.
dc.identifier.citedreferenceBradford CR, Kumar B, Bellile E, et al. Biomarkers in advanced larynx cancer. Laryngoscope. 2014; 124: 179 ‐ 187.
dc.identifier.citedreferenceNdiaye C, Mena M, Alemany L, et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta‐analysis. Lancet Oncol. 2014; 15: 1319 ‐ 1331.
dc.identifier.citedreferenceAhmadi N, Ahmadi N, Chan MV, Huo YR, Sritharan N, Chin R. Laryngeal squamous cell carcinoma survival in the context of human papillomavirus: a systematic review and meta‐analysis. Cureus. 2018; 10: e2234.
dc.identifier.citedreferenceGama RR, Carvalho AL, Longatto Filho A, et al. Detection of human papillomavirus in laryngeal squamous cell carcinoma: systematic review and meta‐analysis. Laryngoscope. 2016; 126: 885 ‐ 893.
dc.identifier.citedreferenceLi X, Gao L, Li H, et al. Human papillomavirus infection and laryngeal cancer risk: a systematic review and meta‐analysis. J Infect Dis. 2013; 207: 479 ‐ 488.
dc.identifier.citedreferenceKalfert D, Celakovsky P, Laco J, Ludvikova M. The role of protein p16(INK4a) in glottic laryngeal squamous cell carcinoma. Pathol Oncol Res. 2014; 20: 909 ‐ 915.
dc.identifier.citedreferenceYoung RJ, Urban D, Angel C, et al. Frequency and prognostic significance of p16(INK4A) protein overexpression and transcriptionally active human papillomavirus infection in laryngeal squamous cell carcinoma. Br J Cancer. 2015; 112: 1098 ‐ 1104.
dc.identifier.citedreferenceBaumann JL, Cohen S, Evjen AN, et al. Human papillomavirus in early laryngeal carcinoma. Laryngoscope. 2009; 119: 1531 ‐ 1537.
dc.identifier.citedreferenceStell PM. Prognosis in laryngeal carcinoma: tumour factors. Clin Otolaryngol. 1990; 15: 69 ‐ 81.
dc.identifier.citedreferenceCoca‐Pelaz A, Rodrigo JP, Suárez C, et al. The risk of second primary tumors in head and neck cancer: a systematic review. Head Neck. 2019. https://doi.org/10.1002/hed.26016.
dc.identifier.citedreferenceShimkin MB. Duration of life in untreated cancer. Cancer. 1951; 4: 1 ‐ 8.
dc.identifier.citedreferenceDepartment of Veterans Affairs Laryngeal Cancer Study Group, Wolf GT, Fisher SG, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991; 324: 1685 ‐ 1690.
dc.identifier.citedreferenceForastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; 349: 2091 ‐ 2098.
dc.identifier.citedreferenceForastiere AA, Zhang Q, Weber RS, et al. Long‐term results of RTOG 91‐11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013; 31: 845 ‐ 852.
dc.identifier.citedreferenceWolf GT, Bellile E, Eisbruch A, et al. Survival rates using individualized bioselection treatment methods in patients with advanced laryngeal cancer. JAMA Otolaryngol Head Neck Surg. 2017; 143: 355 ‐ 366.
dc.identifier.citedreferenceChen AY, Halpern M. Factors predictive of survival in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg. 2007; 133: 1270 ‐ 1276.
dc.identifier.citedreferenceLassig AA, Joseph AM, Lindgren BR, et al. The effect of treating institution on outcomes in head and neck cancer. Otolaryngol Head Neck Surg. 2012; 147: 1083 ‐ 1092.
dc.identifier.citedreferenceGourin CG, Stewart CM, Frick KD, et al. Association of Hospital Volume with laryngectomy outcomes in patients with larynx cancer. JAMA Otolaryngol Head Neck Surg. 2019; 145 ( 1 ): 62 ‐ 70.
dc.identifier.citedreferenceTeppo H, Hyrynkangas K, Koivunen P, Jokinen K, Alho OP. Impact of patient and professional diagnostic delays on the risk of recurrence in laryngeal carcinoma. Clin Otolaryngol. 2005; 30: 157 ‐ 163.
dc.identifier.citedreferenceBray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394 ‐ 424.
dc.identifier.citedreferenceLacy PD, Piccirillo JF, Merritt MG, et al. Head and neck squamous cell carcinoma: better to be young. Otolaryngol Head Neck Surg. 2000; 122: 253 ‐ 258.
dc.identifier.citedreferenceMisono S, Marmor S, Yueh B, et al. Treatment and survival in 10,429 patients with localized laryngeal cancer: a population‐based analysis. Cancer. 2014; 120: 1810 ‐ 1817.
dc.identifier.citedreferenceBrandstorp‐Boesen J, Sorum Falk R, Folkvard Evensen J, Boysen M, Brondbo K. Risk of recurrence in laryngeal cancer. PLoS One. 2016; 11: e0164068.
dc.identifier.citedreferenceStephenson WT, Barnes DE, Holmes FF, Norris CW. G ender influences subsite of origin of laryngeal carcinoma. Arch Otolaryngol Head Neck Surg. 1991; 117: 774 ‐ 778.
dc.identifier.citedreferenceLeoncini E, Vukovic V, Cadoni G, et al. Tumour stage and gender predict recurrence and second primary malignancies in head and neck cancer: a multicentre study within the INHANCE consortium. Eur J Epidemiol. 2018; 33: 1205 ‐ 1218.
dc.identifier.citedreferenceJohansen LV, Grau C, Overgaard J. Laryngeal carcinoma—multivariate analysis of prognostic factors in 1252 consecutive patients treated with primary radiotherapy. Acta Oncol. 2003; 42: 771 ‐ 778.
dc.identifier.citedreferenceLi ZQ, Zou L, Liu TR, Yang AK. Prognostic value of body mass index before treatment for laryngeal squamous cell carcinoma. Cancer Biol Med. 2015; 12: 394 ‐ 400.
dc.identifier.citedreferenceStell PM. Prognostic factors in laryngeal carcinoma. Clin Otolaryngol. 1988; 13: 399 ‐ 409.
dc.identifier.citedreferencevan Bokhorst‐de van der Schueren MA, van Leeuwen PA, Sauerwein HP, Kuik DJ, Snow GB, Quak JJ. Assessment of malnutrition parameters in head and neck cancer and their relation to postoperative complications. Head Neck. 1997; 19: 419 ‐ 425.
dc.identifier.citedreferenceRowan NR, Johnson JT, Fratangelo CE, Smith BK, Kemerer PA, Ferris RL. Utility of a perioperative nutritional intervention on postoperative outcomes in high‐risk head & neck cancer patients. Oral Oncol. 2016; 54: 42 ‐ 46.
dc.identifier.citedreferenceJones C, Badger SA, Hannon R. The role of carbohydrate drinks in pre‐operative nutrition for elective colorectal surgery. Ann R Coll Surg Engl. 2011; 93 ( 7 ): 504 ‐ 507.
dc.identifier.citedreferenceBøje CR, Dalton SO, Grønborg TK, et al. The impact of comorbidity on outcome in 12623 Danish head and neck cancer patients: a population‐based study from the DAHANCA database. Acta Oncol. 2013; 52: 285 ‐ 293.
dc.identifier.citedreferenceCuny F, Meunier A, Heutte N, et al. Laryngeal preservation in ENT oncology. Retrospective series of 246 patients managed in the Caen University Hospital and Francois Baclesse Cancer Care Center between 1998 and 2008. Eur Ann Otorhinolaryngol Head Neck Dis. 2015; 132: 129 ‐ 134.
dc.identifier.citedreferenceSmee RI, De‐loyde KJ, Broadley K, Williams JR. Prognostic factors for supraglottic laryngeal carcinoma: importance of the unfit patient. Head Neck. 2013; 35: 949 ‐ 958.
dc.identifier.citedreferenceStell PM. Prognosis in laryngeal carcinoma: host factors. Clin Otolaryngol Allied Sci. 1990; 15: 111 ‐ 119.
dc.identifier.citedreferenceGrant DG, Hussain A, Hurman D. Pre‐treatment anaemia alters outcome in early squamous cell carcinoma of the larynx treated by radical radiotherapy. J Laryngol Otol. 1999; 113: 829 ‐ 833.
dc.identifier.citedreferenceList MA, Ritter‐Sterr CA, Lansky SB. A performance status for head and neck cancer patients. Cancer. 1990; 66: 564 ‐ 569.
dc.identifier.citedreferenceSpitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients: a concise QL‐index for use by physicians. J Chronic Dis. 1981; 34: 585 ‐ 597.
dc.identifier.citedreferenceCella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993; 11: 570 ‐ 579.
dc.identifier.citedreferenceCharlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373 ‐ 383.
dc.identifier.citedreferenceSabin SL, Rosenfeld RM, Sundaram K, Har‐el G, Lucente FE. The impact of comorbidity and age on survival with laryngeal cancer. Ear Nose Throat J. 1999; 78: 581 ‐ 584.
dc.identifier.citedreferenceList MA, D’Antonio LL, Cella DF, et al. The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy‐head neck scale. A study of utility and validity. Cancer. 1996; 77: 2294 ‐ 2301.
dc.identifier.citedreferencePiccirillo JE, Feinstein AR. Clinical symptoms and comorbidity significance for prognostic classification of cancer. Cancer. 1996; 77: 834 ‐ 842.
dc.identifier.citedreferenceFeinstein AR. The pre‐therapeutic classification of co‐morbidity in chronic disease. J Chron Dis. 1970; 23: 455 ‐ 469.
dc.identifier.citedreferencePiccirillo JF, Wells CK, Sasaki CT, Feinstein AR. New clinical severity staging system for cancer of the larynx. Five‐year survival rates. Ann Otol Rhinol Laryngol. 1994; 103: 83 ‐ 92.
dc.identifier.citedreferenceLiu CT, Chiu TJ, Huang TL, Chien CY, Fang FM. Impact of comorbidity on survival for locally advanced head and neck cancer patients treated by radiotherapy or radiotherapy plus chemotherapy. Chang Gung Med J. 2010; 33 ( 3 ): 283 ‐ 291.
dc.identifier.citedreferenceNao EE, Dassonville O, Chamorey E, et al. Head and neck free‐flap reconstruction in the elderly. Eur Ann Otorhinolaryngol Head Neck Dis. 2011; 128 ( 2 ): 47 ‐ 51. https://doi.org/10.1016/j.anorl.2010.12.001.
dc.identifier.citedreferenceBøje CR. Impact of comorbidity on treatment outcomes in head and neck squamous cell carcinoma – a systematic review. Radiother Oncol. 2014; 100: 81 ‐ 90.
dc.identifier.citedreferenceHuang Z, Han D, Bian Y. The cellular immunologic status of the laryngeal cancer patients in Chinese. Zhonghua Er bi Yan Hou Ke Za Zhi. 1996; 31: 107 ‐ 109.
dc.identifier.citedreferenceRabinovics N, Mizrachi A, Hadar T, et al. Cancer of the head and neck region in solid organ transplant recipients. Head Neck. 2014; 36 ( 2 ): 181 ‐ 186. https://doi.org/10.1002/hed.23283.
dc.identifier.citedreferencehttps://www.cancer.org/cancer/laryngeal-and-hypopharyngeal-cancer/detection-diagnosis-staging/survival-rates.html. (website seer.cancer.gov. Accessed November 22, 2019)
dc.identifier.citedreferenceUnion Internationale Contre le Cancer (International Union Against Cancer). TNM Classification of Malignant Tumours. 4th ed Berlin: Springer‐Verlag; 1987.
dc.identifier.citedreferenceAmerican Joint Committee on Cancer. Manual for staging of cancer. 3rd ed Philadelphia: Lippincott; 1988.
dc.identifier.citedreferenceBailey BJ. Beyond the ’new’ TNM classification. Arch Otolaryngol Head Neck Surg. 1991; 117: 69 ‐ 70.
dc.identifier.citedreferenceLyhne NM, Johansen J, Kristensen CA, et al. Pattern of failure in 5001 patients treated for glottic squamous cell carcinoma with curative intent—a population‐based study from the DAHANCA group. Radiother Oncol. 2016; 118: 257 ‐ 266.
dc.identifier.citedreferenceHakeem AH, Tubachi J, Pradhan SA. Significance of anterior commissure involvement in early glottic squamous cell carcinoma treated with trans‐oral CO 2 laser microsurgery. Laryngoscope. 2013; 123: 1912 ‐ 1917.
dc.identifier.citedreferenceKitani Y, Kubota A, Furukawa M, Sato K. Prognostic factors for local control in patients receiving radiation therapy for early glottic cancer: anterior commissure involvement and effect of chemoradiotherapy. Eur Arch Otorhinolaryngol. 2016; 273: 1011 ‐ 1017.
dc.identifier.citedreferenceFried MP, Ferlito A. In: Ferlito A, Bailey BJ, Rinaldo A, eds. The larynx. Vol II. 3rd ed San Diego: Plural Publishing; 2009: 699 ‐ 709. Chapter 35.
dc.identifier.citedreferenceSilvestri F, Bussani R, Sumtu G, Cosaui C, Ferlito A. Supraglottic versus glottic laryngeal cancer: epidemiological and pathological aspects. ORL J Otorhinolaryngol Relat Spec. 1992; 54: 43 ‐ 48.
dc.identifier.citedreferenceDevaney KO, Hunter BC, Ferlito A, Rinaldo A. Pretreatment pathologic prognostic factors in head and neck squamous cell carcinoma. Ann Otol Rhinol Laryngol. 1997; 106: 983 ‐ 988.
dc.identifier.citedreferenceFagan JJ, Collins B, Barnes L, D’Amico F, Myers EN, Johnson JT. Perineural invasion in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1998; 124 ( 6 ): 637 ‐ 640.
dc.identifier.citedreferenceDemiral AN, Sarioglu S, Birlik B, Sen M, Kinay M. Prognostic significance of EGF receptor expression in early glottic cancer. Auris Nasus Larynx. 2004; 31: 417 ‐ 424.
dc.identifier.citedreferenceBonner J, Giralt J, Harari P, et al. Cetuximab and radiotherapy in laryngeal preservation for cancers of the larynx and Hypopharynx: a secondary analysis of a randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2016; 142: 842 ‐ 849.
dc.identifier.citedreferenceTiefenböck‐Hansson K, Haapaniemi A, Farnebo L, et al. WRAP53β, survivin and p16INK4a expression as potential predictors of radiotherapy/chemoradiotherapy response in T2N0‐T3N0 glottic laryngeal cancer. Oncol Rep. 2017; 38: 2062 ‐ 2068.
dc.identifier.citedreferenceAtef A, El‐Rashidy MA, Elzayat S, Kabel AM. The prognostic value of sex hormone receptors expression in laryngeal carcinoma. Tissue Cell. 2019; 57: 84 ‐ 89.
dc.identifier.citedreferenceRodrigo JP, Ferlito A, Suárez C, et al. New molecular diagnostic methods in head and neck cancer. Head Neck. 2005; 27: 995 ‐ 1003.
dc.identifier.citedreferenceMäkitie AA, Monni O. Molecular profiling of laryngeal cancer. Expert Rev Anticancer Ther. 2009; 9: 1251 ‐ 1260.
dc.identifier.citedreferenceBrennan JA, Mao L, Hruban RH, et al. Molecular assessment of histopathological staging in squamous‐cell carcinoma of the head and neck. N Engl J Med. 1995; 332: 429 ‐ 435.
dc.identifier.citedreferenceBradford CR, Zhu S, Poore J, et al. p53 mutation as a prognostic marker in advanced laryngeal carcinoma. Department of Veterans Affairs Laryngeal Cancer Cooperative Study Group. Arch Otolaryngol Head Neck Surg. 1997; 123: 605 ‐ 609.
dc.identifier.citedreferenceBradford CR, Wolf GT, Carey TE, et al. Predictive markers for response to chemotherapy, organ preservation, and survival in patients with advanced laryngeal carcinoma. Otolaryngol Head Neck Surg. 1999; 121: 534 ‐ 538.
dc.identifier.citedreferenceNylander K, Dabelsteen E, Hall PA. The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck. J Oral Pathol Med. 2000; 29: 413 ‐ 425.
dc.identifier.citedreferenceYuen AP, Lam KY, Choy JT, Ho WK, Wei WI. The clinicopathological significance of bcl‐2 expression in the surgical treatment of laryngeal carcinoma. Clin Otolaryngol Allied Sci. 2001; 26: 129 ‐ 133.
dc.identifier.citedreferenceGrénman J, Homer JJ, Stafford ND. Markers in cancer of the larynx and pharynx. Clin Otolaryngol Allied Sci. 2000; 25: 9 ‐ 18.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
lio2353.pdf
Size:
353.4KB
Format:
PDF
View/Open
Name:
lio2353_am.pdf
Size:
323.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.